AOCNP Cancer Screening and Prevention 4

Question 1

A 45-year-old woman with BRCA1 mutation asks about breast cancer screening recommendations. Which protocol is most appropriate?

Accepted Answer

Annual MRI plus annual mammogram starting at age 25-30

Answer

BRCA1 carriers should begin annual breast MRI and mammogram at age 25-30 due to significantly elevated lifetime risk.

Question 2

Which chemoprevention agent is FDA-approved to reduce breast cancer risk in postmenopausal women with atypical hyperplasia?

Accepted Answer

Both tamoxifen and raloxifene

Answer

Both tamoxifen and raloxifene are FDA-approved for breast cancer risk reduction in postmenopausal high-risk women, including those with atypical hyperplasia.

Question 3

A patient presents with Lynch syndrome. Which cancer screening is NOT part of the standard surveillance protocol?

Accepted Answer

Routine lung CT scan

Answer

Lynch syndrome surveillance does not include routine lung CT; it focuses on colorectal, endometrial, urinary tract, and other Lynch-associated cancers.

Question 4

The HPV vaccine is recommended for which age group as primary prevention against cervical cancer?

Accepted Answer

Ages 9-26, with shared decision-making for ages 27-45

Answer

HPV vaccine is routinely recommended through age 26; shared clinical decision-making guides vaccination for adults aged 27-45.

Question 5

Which stool-based test for colorectal cancer screening requires annual testing and detects both blood and DNA markers?

Accepted Answer

Multi-target stool DNA test (mt-sDNA)

Answer

The multi-target stool DNA test (Cologuard) detects abnormal DNA and hemoglobin and is recommended every 1-3 years.

AOCNP - Advanced Oncology Certified Nurse Practitioner Practice Test

AOCNP - Advanced Oncology Certified Nurse Practitioner Practice Test

AOCNP Cancer Screening and Prevention 4